MAKROLIFE BIOTECH

USING NATURAL IMMUNITY TO FIGHT CANCER

MAKROLIFE BIOTECH

MACROPHAGE REPOLARISATION TECHNOLOGY

IMMUNE SYSTEM RE-PROGRAMMING FOR AN OPTIMIZED TREATMENT OF SOLID TUMOR TYPES

Makrolife Biotech is an integrated pharmaceutical biotechnology company focused on developing Small Molecule therapies to control the immune system for immuno-oncology.

IMMUNOTHERAPY

TUMOR THERAPY BY

MACROPHAGE REPOLARIZATION

THROUGH SMALL MOLECULES

Small Molecules repolarize monocytes and macrophages into an inflammatory anti-tumoral M1 phenotype

IMMUNE SYSTEM TARGETING

AUTOLOGOUS DRUG AND CELL THERAPY

FOR TARGETED TREATMENT OF

SOLID TUMOUR FORMS

The potential to create life-changing cellular therapies

Makrolife Biotech´s unique therapeutic approach

Makrolife Biotech is broadening the therapeutic potential of immunotherapy by targeting macrophages, the master regulator of the immune system. Macrophages can adopt several functional roles in response to signals from their environment.

Our macrophage repolarizing Small Molecules trigger natural biological switches that transform immuno-suppressive M2-like macrophages into pro-inflammatory, anti-tumorigenic macrophages.

These M1-like macrophages not only kill tumor cells, but also set in motion a cascade of signaling molecules that attract and turn on other cancer-fighting immune cells in the tumor microenvironment.

MAKROLIFE BIOTECHUSING NATURAL IMMUNITY TO FIGHT CANCER